Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA approves Lilly obesity pill, triggering battle with Novo Nordisk

 April 1, 2026

BioPharma Dive

Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.

RegulatoryMetabolic & GLP-1Read full story

Post navigation

Lilly bags FDA okay for Wegovy pill rival orforglipron →
← Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com